Welcome to our dedicated page for CATALYST PHARMACEUTICALS SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Catalyst Pharmaceuticals files regulatory disclosures that document material events for its rare-disease biopharmaceutical business and Nasdaq-listed common stock. Recent Form 8-K and 8-K/A filings cover operating results and business updates, Regulation FD presentation materials, press-release exhibits, and capital-structure matters including a board-authorized share repurchase program.
The filings also record company-specific legal and intellectual property disclosures, including FIRDAPSE Orange Book patent litigation, amendments to prior material-event reports, and settlement-related corrections. These documents tie formal disclosures to Catalyst’s commercial products, governance actions, exhibit filings, and public-company reporting obligations.
Catalyst Pharmaceuticals, Inc. (CPRX) director Daniel J. Curran reported new equity awards dated 11/20/2025. He received options to purchase 18,115 shares of common stock at an exercise price of $22.77 per share, which vest in three equal annual installments on November 20, 2026, 2027 and 2028. Following this grant, he beneficially owns 58,115 stock options. He was also awarded 5,468 restricted stock units (RSUs), each representing a right to receive one share of common stock upon vesting, increasing his RSU holdings to 63,583 units. All holdings are reported as directly owned.
Catalyst Pharmaceuticals (CPRX) reported an equity award for its Chief Medical Officer on a Form 4. On November 20, 2025, the officer received options to purchase 98,652 shares of common stock at an exercise price of $22.77 per share, expiring on November 20, 2032. The grant also included 29,776 restricted stock units (RSUs), each representing one share of common stock upon vesting.
The derivative securities vest in three equal parts: one‑third on November 20, 2026, one‑third on November 20, 2027, and one‑third on November 20, 2028. After these awards, the officer beneficially owns 238,360 options and 268,136 RSUs in total, aligning compensation with the company’s long-term stock performance.
Catalyst Pharmaceuticals (CPRX) reported that it issued a press release on November 5, 2025 announcing results for the three and nine months ended September 30, 2025, along with a business update. The press release is furnished as Exhibit 99.1. This routine update signals that quarterly and year-to-date performance details are available via the attached exhibit, which also serves as the company’s formal communication of its latest operating highlights.
Catalyst Pharmaceuticals (CPRX) reported stronger Q3 2025 results. Total revenue reached $148.4 million, up from $128.7 million a year ago, driven by FIRDAPSE ($92.2 million), AGAMREE ($32.4 million), and FYCOMPA ($23.8 million). Operating income was $66.3 million and net income was $52.8 million, with diluted EPS of $0.42 versus $0.35 last year.
For the nine months, revenue rose to $436.4 million from $349.9 million, and net income increased to $161.6 million from $108.0 million. Cash and cash equivalents were $689.9 million, supported by $163.8 million in operating cash flow year-to-date. The balance sheet shows total assets of $1.05 billion, liabilities of $131.4 million, and stockholders’ equity of $920.2 million. Shares outstanding were 122,912,387 as of November 3, 2025.
Catalyst Pharmaceuticals, Inc. disclosed that its Board of Directors has approved a share repurchase program authorizing the company to buy back up to $200 million of its common stock. The program runs from October 1, 2025 through December 31, 2026.
The company may repurchase shares through methods such as open market purchases or privately negotiated transactions. The timing and amount of any repurchases will depend on factors including stock price, business and market conditions, regulatory requirements, and alternative investment or acquisition opportunities. Catalyst plans to use existing cash on hand to fund the program, is not obligated to repurchase any specific amount, and may suspend or terminate the program at any time.
Brian Elsbernd, Chief Compliance/Legal Officer and Director of Catalyst Pharmaceuticals, reported option exercises and an open-market sale on 09/08/2025. He exercised 112,475 options at an exercise price of $2.24 per share, resulting in the acquisition of 112,475 common shares. To fund the exercise price and tax withholding, 30,000 shares were sold on the open market at a weighted average price of $20.30 (sales ranged from $20.225 to $20.315). Following these transactions, Mr. Elsbernd beneficially owned 271,039 shares directly and reported 846,609 derivative securities (options) beneficially owned. The options reported vested in three annual tranches beginning December 19, 2019.
Catalyst Pharmaceuticals (CPRX) filing a Form 144 notifies of a proposed sale of 30,000 common shares to be executed through Fidelity Brokerage Services on 09/08/2025 with an aggregate market value of $609,035.49 based on the filing. The shares were acquired through options granted 12/19/2018 and the reported payment method for the sale is cash. The filing also reports recent open-market disposals by the same person: 20,000 shares sold on 09/03/2025 for $401,514.00 and 30,000 shares sold on 09/04/2025 for $585,642.00. The filer attests no undisclosed material adverse information.
Catalyst Pharmaceuticals insider Brian Elsbernd, listed as the company's Chief Compliance/Legal Officer, reported option exercises and open-market sales on 09/03/2025 and 09/04/2025. He exercised 20,000 options on 09/03/2025 at a $2.24 exercise price and sold 20,000 common shares that day for a weighted average of $20.08 per share. On 09/04/2025 he exercised another 30,000 options at $2.24 and sold 30,000 shares for a weighted average of $19.52 per share. Following these transactions his beneficial ownership in common stock is reported as 188,564 shares and the filing shows remaining option positions underlying 989,084 and 959,084 shares after each exercise event as reported in Table II. The filing states the sales were on the open market for personal reasons and not due to any disagreement with the company.
Catalyst Pharmaceutical, Inc. (CPRX) filing a Form 144 notifies the proposed sale of 30,000 common shares through Fidelity Brokerage Services with an aggregate market value of $585,640.54. The shares represent options granted on 12/19/2018 and were acquired on 09/04/2025; payment is expected in cash. The filing lists 122,391,010 shares outstanding and names NASDAQ as the exchange for an approximate sale date of 09/04/2025. It also discloses a recent sale of 20,000 shares by Brian Elsbernd on 09/03/2025 for gross proceeds of $401,514.00. The filer certifies no undisclosed material adverse information.
Catalyst Pharmaceuticals (CPRX) reports a proposed Rule 144 sale of 20,000 common shares, to be transacted through Fidelity Brokerage Services on NASDAQ with an aggregate market value of $401,514.10. The shares were acquired on 09/03/2025 via exercise of options originally granted on 12/19/2018, and payment for those shares is noted as cash. The filing indicates 122,391,010 shares outstanding for the issuer and states there were no securities sold by the reporting person in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.